The endocannabinoid anandamide activates pro-resolving pathways in human primary macrophages by engaging both CB
Humans
Endocannabinoids
/ metabolism
Receptor, Cannabinoid, CB2
/ metabolism
Polyunsaturated Alkamides
/ pharmacology
Arachidonic Acids
/ pharmacology
Macrophages
/ metabolism
Receptors, G-Protein-Coupled
/ metabolism
Inflammation
/ metabolism
Cells, Cultured
Signal Transduction
/ drug effects
Docosahexaenoic Acids
/ pharmacology
Arachidonate 5-Lipoxygenase
/ metabolism
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
revised:
30
04
2024
received:
04
07
2023
accepted:
07
05
2024
medline:
27
5
2024
pubmed:
27
5
2024
entrez:
27
5
2024
Statut:
ppublish
Résumé
Resolution of inflammation is the cellular and molecular process that protects from widespread and uncontrolled inflammation and restores tissue function in the aftermath of acute immune events. This process is orchestrated by specialized pro-resolving mediators (SPM), a class of bioactive lipids able to reduce immune activation and promote removal of tissue debris and apoptotic cells by macrophages. Although SPMs are the lipid class that has been best studied for its role in facilitating the resolution of self-limited inflammation, a number of other lipid signals, including endocannabinoids, also exert protective immunomodulatory effects on immune cells, including macrophages. These observations suggest that endocannabinoids may also display pro-resolving actions. Interestingly, the endocannabinoid anandamide (AEA) is not only known to bind canonical type 1 and type 2 cannabinoid receptors (CB
Identifiants
pubmed: 38801406
doi: 10.1096/fj.202301325R
doi:
Substances chimiques
Endocannabinoids
0
anandamide
UR5G69TJKH
Receptor, Cannabinoid, CB2
0
Polyunsaturated Alkamides
0
Arachidonic Acids
0
Receptors, G-Protein-Coupled
0
GPR18 protein, human
0
Docosahexaenoic Acids
25167-62-8
Arachidonate 5-Lipoxygenase
EC 1.13.11.34
CNR2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23675Subventions
Organisme : Ministero della Salute
ID : PNRR-MAD-2022-12376730
Informations de copyright
© 2024 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro‐resolving superfamily of mediators. J Clin Invest. 2018;128:2657‐2669.
Serhan CN. Discovery of specialized pro‐resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Asp Med. 2017;58:1‐11.
Dalli J, Serhan CN. Pro‐resolving mediators in regulating and conferring macrophage function. Front Immunol. 2017;8: 1400.
Chiurchiù V, Leuti A, Dalli J, et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci Transl Med. 2016;8:353ra111.
Leuti A, Fazio D, Fava M, Piccoli A, Oddi S, Maccarrone M. Bioactive lipids, inflammation and chronic diseases. Adv Drug Deliv Rev. 2020;159:133‐169.
Chiurchiù V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018;9:38.
Chiurchiù V, Scipioni L, Arosio B, Mari D, Oddi S, Maccarrone M. Anti‐inflammatory effects of fatty acid amide hydrolase inhibition in monocytes/macrophages from Alzheimer's disease patients. Biomolecules. 2021;11:502.
Cencioni MT, Chiurchiù V, Catanzaro G, et al. Anandamide suppresses proliferation and cytokine release from primary human T‐lymphocytes mainly via CB2 receptors. PLoS One. 2010;5:e8688.
Leuti A, Fava M, Pellegrini N, Maccarrone M. Role of specialized pro‐resolving mediators in neuropathic pain. Front Pharmacol. 2021;12:717993.
Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015;212:1203‐1217.
Console‐Bram L, Brailoiu E, Brailoiu GC, Sharir H, Abood ME. Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol. 2014;171:3908‐3917.
Jiang L, Chen Y, Huang X, et al. Selective activation of CB2 receptor improves efferocytosis in cultured macrophages. Life Sci. 2016;161:10‐18.
Flak MB, Koenis DS, Sobrino A, et al. GPR101 mediates the pro‐resolving actions of RvD5n‐3 DPA in arthritis and infections. J Clin Invest. 2020;130:359‐373.
Koenis DS, Beegun I, Jouvene CC, et al. Disrupted resolution mechanisms favor altered phagocyte responses in COVID‐19. Circ Res. 2021;129:e54‐e71.
Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 2009;37:W652‐W660.
Chiurchiù V, Leuti A, Cencioni MT, et al. Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct toll‐like receptors. Pharmacol Res. 2016;113:313‐319.
Cabral GA, Ferreira GA, Jamerson MJ. Endocannabinoids and the immune system in health and disease. In: Pertwee RG, ed. Endocannabinoids. Springer International Publishing; 2015:185‐211.
Rymut N, Heinz J, Sadhu S, et al. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell‐induced MerTK cleavage. FASEB J. 2020;34:597‐609.
Ross RA, Brockie HC, Stevenson LA, et al. Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol. 1999;126:665‐672.
De Petrocellis L, Schiano Moriello A, Imperatore R, Cristino L, Starowicz K, Di Marzo V. A re‐evaluation of 9‐HODE activity at TRPV1 channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons. Br J Pharmacol. 2012;167:1643‐1651.
Lee G, Elwood F, McNally J, et al. T0070907, a selective ligand for peroxisome proliferator‐activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002;277:19649‐19657.
Morales P, Lago‐Fernandez A, Hurst DP, et al. Therapeutic exploitation of GPR18: beyond the cannabinoids? J Med Chem. 2020;63:14216‐14227.
Komarnytsky S, Rathinasabapathy T, Wagner C, et al. Endocannabinoid system and its regulation by polyunsaturated fatty acids and full Spectrum hemp oils. Int J Mol Sci. 2021;22:5479.
Maccarrone M, Di Marzo V, Gertsch J, et al. Goods and Bads of the endocannabinoid system as a therapeutic target: lessons Learned after 30 years. Pharmacol Rev. 2023;75:885‐958.
Liu J, Batkai S, Pacher P, et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3‐kinase/NF‐kappaB independently of platelet‐activating factor. J Biol Chem. 2003;278:45034‐45039.
Liu J, Wang L, Harvey‐White J, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2008;54:1‐7.
Jiang L, Pu J, Han Z, Hu L, He B. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res. 2009;81:805‐813.
Steffens S, Pacher P. Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. Br J Pharmacol. 2012;167:313‐323.
Reyes‐Resina I, Navarro G, Aguinaga D, et al. Molecular and functional interaction between GPR18 and cannabinoid CB2 G‐protein‐coupled receptors. Relevance in neurodegenerative diseases. Biochem Pharmacol. 2018;157:169‐179.
O'Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173:1899‐1910.
Muller C, Lynch DL, Hurst DP, Reggio PH. A closer look at anandamide interaction with TRPV1. Front Mol Biosci. 2020;7:144.
Yoon Y‐S, Kim S‐Y, Kim M‐J, Lim J‐H, Cho M‐S, Kang JL. PPARγ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines. Mucosal Immunol. 2015;8:1031‐1046.
Fernandez‐Boyanapalli R, Frasch SC, Riches DWH, Vandivier RW, Henson PM, Bratton DL. PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood. 2010;116:4512‐4522.
Gordon S, Plüddemann A. Tissue macrophages: heterogeneity and functions. BMC Biol. 2017;15:53.
Werz O, Gerstmeier J, Libreros S, et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun. 2018;9:59.
Elliott MR, Koster KM, Murphy PS. Efferocytosis signaling in the regulation of macrophage inflammatory responses. J Immunol. 2017;198:1387‐1394.
Braun M, Khan ZT, Khan MB, et al. Selective activation of cannabinoid receptor‐2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain Behav Immun. 2018;68:224‐237.
Du Y, Ren P, Wang Q, et al. Cannabinoid 2 receptor attenuates inflammation during skin wound healing by inhibiting M1 macrophages rather than activating M2 macrophages. J Inflamm. 2018;15:25.
Tomar S, Zumbrun E, Nagarkatti M, Nagarkatti PS. Protective role of cannabinoid receptor 2 activation in galactosamine/lipopolysaccharide‐induced acute liver failure through regulation of macrophage polarization and microRNAs. J Pharmacol Exp Ther. 2015;353:369‐379.
Tanaka M, Sackett S, Zhang Y. Endocannabinoid modulation of microglial phenotypes in neuropathology. Front Neurol. 2020;11: 87.
Lin J, Xu A, Jin J, et al. MerTK‐mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD‐L1 expression. Onco Targets Ther. 2022;11:2024941.
Zhou Y, Fei M, Zhang G, et al. Blockade of the phagocytic receptor MerTK on tumor‐associated macrophages enhances P2X7R‐dependent STING activation by tumor‐derived cGAMP. Immunity. 2020;52:357‐373.e9.
Zolese G, Wozniak M, Mariani P, Saturni L, Bertoli E, Ambrosini A. Different modulation of phospholipase A2 activity by saturated and monounsaturated N‐acylethanolamines. J Lipid Res. 2003;44:742‐753.
Zhang Y, Olson RM, Brown CR. Macrophage LTB4 drives efficient phagocytosis of borrelia burgdorferi via BLT1 or BLT2. J Lipid Res. 2017;58:494‐503.
Li P, Oh DY, Bandyopadhyay G, et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015;21:239‐247.
Peltner LK, Gluthmann L, Börner F, et al. Cannabidiol acts as molecular switch in innate immune cells to promote the biosynthesis of inflammation‐resolving lipid mediators. Cell Chem Biol. 2023;30:1508‐1524.e7.
Leuti A, Fava M, Maccarrone M. A game of networks: do different lipids interact to orchestrate inflammatory homeostasis? Cell Chem Biol. 2023;30:1499‐1501.